Remogliflozin

Overview

Remogliflozin (Remogliflozin A) is an orally active, highly selective sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor, with a K i of 12.4 nM for human SGLT2 and 26.0 nM for rat SGLT2 . Remogliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption. Without insulin stimulation, remogliflozin suppresses the elevation of plasma glucose, reduces fasting blood glucose and glycated hemoglobin , and improves glycosuria, hyperglycemia, hyperinsulinemia, hypertriglyceridemia and insulin resistance in diabetic rodents. Remogliflozin can be used in research related to type 2 diabetes.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > SGLT

Product Information

• Catalog No.: HY-13414
• CAS No.: 329045-45-6
• Molecular Formula: C23H34N2O7
• Molecular Weight: 450.53
• Purity: 99.5%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source